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Peptide receptor radionuclide therapy is a new treatment modality for patients with inoperable or
metastasised neuroendocrine gastroenteropancreatic tumours. After the successful implementation
of somatostatin receptor scintigraphy in daily clinical practice, the next logical step was to increase
the radiation dose of the administered radiolabelled somatostatin analogue in an attempt to induce
tumour shrinkage. Since then, an increasing numberof patients has been successfully treated with this
approach, resulting in a substantial numbers of patient with objective tumour shrinkage. Serious side-
effects have been rare. This article reviews the effectiveness of the different radiolabelled
somatostatin analogues used, the currently known side-effects and the survival data available.
Furthermore, clinical issues, including indication and timing of therapy, are discussed. Finally,
important directions for future research are briefly mentioned to illustrate that, although the
currently available results already suggest a favourable outcome compared with other systemic
therapies, new strategies are being developed to increase efficacy.
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596 J. J. M. Teunissen et alSomatostatin receptor (SSTR) scintigraphy, which was developed in the late 1980s, has
become an important image modality in patients with SSTR-positive tumours.1,2 This is
not only because of its high sensitivity for visualising somatostatin-positive tumours and
thereby its ability to localise otherwise undetectable disease, but also because of the
selection of known metastatic disease for peptide receptor radionuclide therapy
(PRRT) with radiolabelled somatostatin analogues. This new modality of targeted
therapy is very promising, especially in patients with inoperable or metastatic
gastroenteropancreatic (GEP) tumours (i.e. gastrointestinal carcinoids and functioning
and non-functioning pancreatic endocrine tumours).RADIONUCLIDES AND SOMATOSTATIN ANALOGUES IN PEPTIDE
RECEPTOR RADIONUCLIDE THERAPY
Several radiolabelled somatostatin analogues are currently used to treat patients with
SSTR-positive metastasised GEP tumours. These conjugates all consist of a
somatostatin analogue, such as octreotide or octreotate, a complexing moiety (or
chelator) and a radionuclide. The chelator, which is attached to the somatostatin
analogue, allows a stable connection between the analogue and the radionuclide. The
basic principle of tumour-targeting after systemic administration of the conjugate
involves binding to SSTRs, which are expressed on the cell surface of the tumour cell,
followed by effective internalisation of the radionuclide-peptide complex.3–5 The
emitted radiation can damage the DNA, which may subsequently lead to the induction
of cell death. In clinical practice, different combinations of radionuclides and
somatostatin analogues are used to target the SSTR-positive tumour. These analogues
differ from each other in their affinity for the various SSTR subtypes. This variable
affinity is important because it can have great influence on the clinical effectiveness of
the radiolabelled somatostatin analogue. The available radionuclides and somatostatin
analogues used will be discussed.
Radionuclides in peptide receptor radionuclide therapy
Indium (111In), yttrium (90Y) and lutetium (177Lu) have been the most frequently used
radionuclides for targeted radiotherapy in the various clinical trials over the past
decade. Differences in the physical properties of these radionuclides, which are
important for the effectiveness of the therapy, relate to, for example, emitted particles,
particle energy and tissue penetration range (Table 1). 111In, coupled via the chelator
DTPA to D-Phe1-octreotide ([111In-DTPA0]octreotide; 111In-octreotide), was used in
the first clinical trials in which patients with metastasised GEP tumours were
treated with radiolabelled somatostatin analogues.6–8 Besides g-radiation, which makes
111In a suitable radionuclide for imaging, it emits both Auger and conversion electrons
with a medium-to-short tissue penetration range (0.02–10 and 200–500 mm,
respectively). In vitro PRRT studies with [111In-DTPA0]octreotide showed that the
therapeutic effect was dependent on internalisation, which enables the Auger electrons
to reach the nucleus.9 These results suggest that the Auger electrons and not the
conversion electrons can be held responsible for the reported tumour responses with
111In-labelled somatostatin analogues.
In an attempt to increase the efficacy of PRRT, clinical trials that followed used
b-emitting radionuclides, such as 90Y or 177Lu. Radionuclides emitting b-radiation have
Table 1. Physical characteristics of the radionuclides used in peptide receptor radionuclide therapy.
Radionuclides
Emitted
particle
Particle energy
(mean keV)
Maximum tissue penetration
range (approximate number
of cellsa) Half-life (days)
Indium (111In) Auger
electrons
3 and 19 keV 10 mm (!1) 2.8
g-radiation 171 and
245 keV
Yttrium (90Y) b-radiation 935 keV 12 mm (approximately 600) 2.7
Lutetium (177Lu) b-radiation 130 keV 2 mm (approximately 100) 6.7
g-radiation 113 and
208 keV
a Number of cells based on an average tumour cell size of 20 mm.
Peptide receptor radionuclide therapy 597greater therapeutic potential since the emitted particle range exceeds the cell
diameter.10–12 Furthermore, the ability to irradiate neighbouring cells is an advantage
with tumours, such as breast carcinomas, that are characterised by a heterogeneous
SSTR tissue distribution, with regions of high density next to regions that lack receptor
expression.13 As expected, the clinical and preclinical studies in which 90Y- or 177Lu-
coupled somatostatin analogues were used demonstrated more effectiveness in
terms of tumour shrinkage than was reported with somatostatin analogues coupled to
111In.14–17 O’Donoghue et al,12 who used a mathematical model to examine tumour
curability and its relationship to tumour size for 22 b-emitting radionuclides, calculated
an optimal tumour diameter for cure of 34 and 2 mm for 90Y and 177Lu, respectively.
With respect to these calculations, the preclinical studies by de Jong et al,14,18 in
which Lewis rats bearing SSTR-positive pancreatic CA20948 tumours of different
sizes (0.1–15 cm2) were treated with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTA-
TATE) and [90Y-DOTA0,Tyr3]octreotide (90Y-DOTATOC) are of special interest.
After treatment with 177Lu-DOTATATE (total cumulative dose 555 MBq, maximum
estimated tumour dose 60 Gy), a higher cure rate was observed in the group of rats
bearing small tumours (%1 cm2) than in the rats bearing larger tumours (R1 cm2,
mean approximately 5 cm2). In contrast, treatment with a single dose of 370 MBq
90Y-DOTATOC, leading up to a maximum of 60 Gy in the medium-sized (3–9 cm2)
tumours, showed less cure within the group of rats bearing small (%1 cm2) tumours
compared with the rats bearing medium-sized tumours (Figure 1).19 These results
suggested that treatment with a combination of 90Y- and 177Lu-labelled somatostatin
analogues can be more effective in the treatment of multiple tumours that differ in size
than can one of the analogues separately. Recently, de Jong et al20 reported the
results of such a combination versus single analogue therapy. In rats bearing both a small
(!0.5 cm2) and a large tumour (7–9 cm2), significantly better survival was observed
after PRRTwith the combination of 185 MBq (half-dose) 90Y-DOTATOC and 278 MBq
(half-dose) 177Lu-DOTATATE than after a single full dose of 370 MBq 90Y-DOTATOC or
555 MBq 177Lu-DOTATATE.
To translate these results to the clinical setting with patients with GEP tumours,
90Y-labelled somatostatin analogues may be more effective in larger tumours, whereas
177Lu-labelled somatostatin analogues may be more effective in smaller tumours, with
the combination of both radionuclides as the most suitable therapy for the clinical
[90Y-DOTA0, Tyr3]octreotide
< 1 cm2 3-9 cm2
0
25
50
75
100 CR
PR
pe
rc
en
ta
ge
 (%
)
[177Lu-DOTA0, Tyr3]octreotate
< 1 cm2 > 1 cm2
0
25
50
75
100 CR
PR
pe
rc
en
ta
ge
 (%
)
Figure 1. Cure rate (expressed as percentage of cured rats) found in groups of rats bearing CA20948
tumours of different indicated sizes after treatment with 370 MBq[90Y-DOTA0, Tyr3]octreotide or
555 MBq[177Lu-DOTA0, Tyr3]octreotate (maximum estimated tumour dose of 60 Gy for both treatments).
CR, complete response; PR, partial response. (Modified from de Jong et al.14).
598 J. J. M. Teunissen et alsituation in which most patients have tumour metastases varying in size. Unfortunately,
randomised controlled clinical studies comparing the therapeutic efficacy of 90Y and
177Lu somatostatin analogues or combination-based regimens are still lacking.Somatostatin analogues in peptide receptor radionuclide therapy
The various 111In-, 90Y- or 177Lu-labelled somatostatin analogues differ in their affinity
for the expressed SSTRs. Five human SSTR subtypes (SSTR1–SSTR5) that bind native
human somatostatin (SS14) and its high-affinity 28 amino acid precursor (SS28) have
been cloned.21–23 However, their affinities for synthetic somatostatin analogues differ
considerably. The ‘cold’ analogue octreotide, which is frequently used to control
symptoms related to hormone overproduction by GEP tumours, binds with high affinity
to SSTR2 and with low affinity to SSTR3 and SSTR5, whereas it does not bind to SSTR1
and SSTR4.24,25 Furthermore, autoradiography studies by Reubi et al26 demonstrated
that, after labelling octreotide, via DTPA, with111In, the affinities to SSTR2 and SSTR5
were diminished (Table 2). However, despite the change in affinities, SSTR2
Table 2. Affinity profiles (IC50)
a for human somatostatin receptors SSTR1–SSTR5 (hSSTR1–hSSTR5) of a
series of somatostatin analogues.
Peptides hSSTR1 hSSTR2 hSSTR3 hSSTR4 hSSTR5
Somatostatin-28 5.2G0.3 (19) 2.7G0.3 (19) 7.7G0.9 (19) 5.6G0.4 (19) 4.0G0.3 (19)
Octreotide O10,000 (5) 2.0G0.7 (5) 187G55 (3) O1,000 (5) 22G6 (5)
DTPA-octreotide O10,000 (6) 12G2 (5) 376G84 (5) O1,000 (5) 299G50 (6)
111In-octreotide O10,000 (5) 22G3.6 (5) 182G13 (5) O1,000 (5) 237G52 (5)
DOTATOC O10,000 (7) 14G2.6 (6) 880G324 (4) O1,000 (6) 393G84 (6)
90Y- DOTATOC O10,000 (4) 11G1.7 (6) 389G135 (5) O10,000 (5) 114G29 (5)
DOTALAN O10,000 (7) 26G3.4 (6) 771G229 (6) O10,000 (4) 73G12 (6)
90Y-DOTALAN O10,000 (3) 23G5 (4) 290G105 (4) O10,000 (4) 16G3.4 (4)
DOTA-OC O10,000 (3) 14G3 (4) 27G9 (4) O1,000 (4) 103G39 (3)
90Y-DOTA-OC O10,000 (5) 20G2 (5) 27G8 (4) O10,000 (4) 57G22 (4)
DTPA-Tyr3-
octreotate
O10,000 (4) 3.9G1 (4) O10,000 (4) O1,000 (4) O1,000 (4)
111In-DTPA-Tyr3-
octreotate
O10,000 (3) 1.3G0.2 (3) O10,000 (3) 433G16 (3) O1,000 (3)
DOTA-Tyr3-
octreotate
O10,000 (3) 1.5G0.4 (3) O1,000 (3) 453G176 (3) 547G160 (3)
90Y-DOTA-Tyr3-
octreotate
O10,000 (3) 1.6G0.4 (3) O1,000 (3) 523G239 (3) 187G50 (3)
Modified from Reubi et al.26
a All values are IC50GSEM in nM. The number of experiments is in parentheses.
Peptide receptor radionuclide therapy 599remains the receptor subtype for which [111In-DTPA0]octreotide has the
highest affinity. Hofland et al27 demonstrated that the uptake of [111In-DTPA0]octreo-
tide in the SSTR-positive organs of mice was predominantly determined by SSTR2.
Moreover, John et al28 demonstrated that a positive [111In-DTPA0]octreotide
scintigram in patients with neuroendocrine tumours is mainly the result of
SSTR2 expression, whereas SSTR1, SSTR3, SSTR4 and probably SSTR5 are less
important.
Radiolabelled somatostatin analogues that had a higher affinity for SSTR2 than did
111In-octreotide, and were therefore potentially more effective for therapy, thus
became available. Small structural changes in the radioligand molecule, for example a
different radionuclide, chelator or peptide, revealed distinct differences in the
binding properties of the analogue for the various SSTR subtypes (Table 2).26 In
animal experiments, several 111In-labelled somatostatin analogues showed a higher
specific uptake than 111In-labelled [DTPA0]octreotide in SSTR-positive organs.5
Furthermore, the analogue [DOTA0, Tyr3]octreotate has a ninefold higher affinity for
SSTR2 compared with [DOTA0, Tyr3]octreotide, whereas the affinities for SSTR3
and SSTR5 were found to be lower.26 In line with the higher affinity for SSTR2,
biodistribution studies on 111In-octreotide and 177Lu-DOTATATE scintigraphy
showed a three- to fourfold higher tumour uptake in four out of five patients
with somatostatin-positive tumours, of whom three had GEP tumours.29 As most
GEP tumours are known to predominantly express SSTR2, all clinical studies
selected a radiolabelled somatostatin analogue for PRRT with at least a high affinity
for SSTR2.
600 J. J. M. Teunissen et alCLINICAL STUDIES
The outcome of several phase I and phase II PRRT studies, in which different
radiolabelled somatostatin analogues were used, has been published. In addition, it has
become apparent that the bone marrow and kidneys are the most important dose-
limiting organs in this type of therapy.[111In-DTPA0]octreotide
The first radiolabelled somatostatin analogue therapy in GEP patients with advanced-
stage disease was based on the administration of high dosages of 111In-octreotide,
which at that time was available for diagnostic purposes (Table 3).6,7,30,31 The total
cumulative dose varied from 3.1 GBq up to 160.0 GBq.
In a report by Valkema et al,6 in which the outcome of 111In-octreotide treatment in
50 patients with SSTR-positive tumours was reviewed, 15 out of the 26 (58%) GEP
patients had a stabilisation of their metastatic disease, and two out of 26 (8%) showed
minor remission, defined as a reduction in tumour size of between 25% and 50%.
Patients with stable disease and minor remission (17 out of 26; 65%) were considered
to have shown a beneficial therapeutic effect as all patients had documented
progressive disease at study entry. In another report by Anthony et al,30 2 out of 26
(8%) patients had a partial remission, whereas 21 out of 26 (81%) had stable disease.
Buscombe et al31 reported the outcome of 111In-octreotide therapy in 12 GEP patients
treated with cumulative activities as high as 36.6 GBq. Seven out of the 12 (58%)
patients had stable disease 6 months after the last therapy, 2 (17%) demonstrated
partial remission and 3 (25%) had progressive disease despite treatment.Table 3. Peptide receptor radionuclide therapy with 111In-octreotide in patients with gastroenter-
opancreatic tumours.
Authors
Number
of
patients
PD before
therapy
Cum dose
(GBq)
Responsea
PR MRb SD PD
Valkema
et al6
26 24/26 (92%)
(clinical and/
or imaging
based)
4.7–160.0 0 2 (8%) 15 (58%) 9 (35%)
Anthony
et al30
26 100% (clinical
and/or ima-
ging based)
6.7–46.6 2 (8%) N/I 21 (81%) 3 (11%)
Buscombe
et al31
12 100% (bio-
chemical
or imaging
based)
3.1–36.6 2 (17%) N/I 7 (58%) 3 (25%)
Cum dose, cumulative dose of 111In-octreotide; N/I, not indicated.
a Criteria of tumour response: PR (partial remission), O50% reduction in tumour size; MR, xxxxx; SD
(stable disease), G25% reduction or increase in tumour size; PD (progressive disease), O25% increase in
tumour size.
b Modification of SWOG criteria including MR (minor remission), between 25 and 50% reduction in
tumour size.
Peptide receptor radionuclide therapy 601All the clinical PRRT studies reported encouraging and promising results, especially
in terms of clinical benefit and biochemical responses. Reported cases of objective
tumour shrinkage were, however, few. These outcomes suggested that the anti-tumour
effect of 111In-octreotide is not ideal for PRRT, at least for visible GEP tumours.
However, experimental data in rats have shown that high doses of 111In-octreotide can
inhibit the growth of liver metastases after injecting SSTR2 receptor-positive tumour
cells into the portal vein.32 These results suggest that PRRT with 111In-labelled
analogues might be effective in the treatment of micro-metastases or metastatic spread
during initial surgery. Clinical studies that could confirm these observations are,
however, lacking.[90Y-DOTA0, Tyr3]octreotide, [90Y-DOTA]lanreotide
and [90Y-DOTA0,Tyr3]octreotate
In the clinical trials that followed the PRRT with 111In-labelled analogues, 90Y-labelled
analogues were used. A summary of these studies is shown in Table 4.
In 1998, Otte et al33 reported the first results of 10 patients with SSTR-positive
tumours treated with 90Y-DOTATOC. Two out of 10 patients had partial remission and
six stable disease; in two patients, 18F-deoxyglucose positron emission tomography,
after a single dose of 90Y-DOTATOC, showed a substantial reduction of 18F-deoxy-
glucose uptake in the tumour. In the studies that followed, the response rates
(complete and partial remission) in patients with GEP tumours, who were treated with
either 6.0 GBq/m2 or 7.4 GBq/m2, were 10 out 37 (27%) and 8 out of 37 (22%),
respectively.16,34 To determine whether a decrease in the number of treatments, but at
the same time maintaining the maximum cumulative dose of 7.4 GBq/m2 due to an
increase of dosage per treatment, could increase the objective response another study
was performed.35 Twelve out of 35 patients (34%) had complete or partial remission,
which indicated a higher percentage of tumour regression. No increase in the number
of side-effects was reported.
Although these results suggested that an increase of dose, and as a consequence a
decrease in the number of therapeutic injections, could be more beneficial, it must be
stressed that this was not a randomised controlled trial and the number of treated
patients was low. Nonetheless, the variation of protocol characteristics, such as the
number of treatments, the doses per treatment or the length of treatment interval, are of
great interest and may play an important role in the reported outcome of PRRT studies.
Randomised controlled studies on the effects of these variables are therefore needed.
Clinical studies performed in Milan also used 90Y-DOTATOC to treat various SSTR-
positive tumours.36–40 Recently, Bodei et al40 reported their experience with
90Y-DOTATOC, in which a total of 141 patients with various, somatostatin-positive
tumours were treated. An objective response (complete or partial remission) of 26%
was observed. More precisely, 23% of patients who had progressive disease before
therapy (113 out of 141; 80%) had complete or partial remission, whereas in the group
with stable disease (28 out of 141; 20%), 32% had complete or partial remission.
Unfortunately, the specified treatment outcome according to tumour type was not
given. It was, however, reported that most of the patients who had a favourable
outcome had neuroendocrine GEP tumours. In a more detailed study from Milan, the
outcome of therapy in 40 patients with SSTR-positive tumours was reported.39 The
cumulative dose of 90Y-DOTATOC, which was given in two cycles, ranged from 5.9 to
11.1 GBq. In the group with GEP tumours, this therapy regimen resulted in partial
Table 4. Peptide receptor radionuclide therapy with 90Y- and 177Lu-labelled somatostatin analogues in
patients with gastroenteropancreatic tumours.
Authors
Number
of
patients
PD at
baseline
Responsea
CR PR MRb SD PD CRCPR
[90Y-DOTA0, Tyr3]octreotide
Otte
et al48
16 N/I 0 1 (6%) N/I 14 (88%) 1 (6%) 1/16
(6%)
Waldherr
et al34
37 34/37
(84%)
1 (3%) 9 (24%) N/I 23 (62%) 4 (11%) 10/37
(27%)
Waldherr
et al16
37 37/37
(100%)
1 (3%) 7 (19%) N/I 6 (70%) 3 (8%) 8/37
(22%)
Waldherr
et al35
35 35/35
(100%)
2 (6%) 10 (29%) N/I 19 (54%) 4 (11%) 12/35
(34%)
Bodei
et al39
21 N/I 0 6 (29%) N/I 11 (52%) 4 (19%) 6/21
(29%)
Valkema
et al41
54 41/54c
(76%)
0 4 (7%) 7 (13%) 33 (61%) 10 (19%) 4/54
(7%)
[90Y-DOTA]lanreotide
Virgolini
et al15
39 39/39
(100%)
0 0 8 (20%) 17 (44%) 14 (36%) 0/39
(0%)
[90Y-DOTA0,Tyr3]octreotate
Baum
et al43,44
75 67/75
(89%)
0 28 (37%) N/I 39 (52%) 8 (11%) 28/75
(37%)
[177Lu-DOTA0,Tyr3]octreotate
Kwekke-
boom
et al45
76 29/76
(38%)
1 (1%) 22 (29%) 9 (12%) 30 (39%) 14 (18%) 23/76
(30%)
N/I, not indicated.
a Criteria of tumour response (SWOG); CR (complete remission), no evidence of disease; PR (partial
remission), O50%reduction in tumour size; SD (stable disease), G25% reduction or increase in tumour
size; PD (progressive disease), O25% increase in tumour size.
b Modification of SWOG criteria including MR (minor remission), between 25 and 50% reduction in
tumour size.
c R. Valkema, personal communication, 2004.
602 J. J. M. Teunissen et alremission in 6 out of 21 patients (29%), whereas 11 out of 21 (52%) had stable disease
and 4/21 (19%) had progressive disease.
Valkema et al41 reported the preliminary results of a multicentre phase I study
performed in Rotterdam, Brussels and Tampa. The objective was to define the
maximum tolerated single and four-cycle doses of 90Y-DOTATOC.6,11,14 Escalating
doses up to 14.8 GBq/m2 in four doses or up to 9.3 GBq/m2 in a single dose were
administered to a total of 60 patients. Four of the 54 (7%) patients who were treated
with their maximum allowed dose had partial remission, 7 out of 54 (13%) had minor
remission, and 33 out of 54 (61%) showed stabilisation of their disease. Anti-tumour
effect in terms of improvement of response, according to the SWOG (Southwest
Oncology Group) tumour response criteria, including stable disease and minor
remission in patients with progressive disease at the start of therapy, was reported as
65%.41 The median time to progression of that same group had not been reached at
26 months.42
Peptide receptor radionuclide therapy 603In a European multicentre study (MAURITIUS), another 90Y-labelled somatostatin
analogue, 90Y-DOTA-lanreotide, was used to treat 39 GEP patients. The total
cumulative dose ranged from 1.9 GBq to 8.6 GBq (50–232 mCi) of 90Y-DOTA-
lanreotide.15 Eight out of 39 (20%) patients showed minor remission, and 17 out of 39
(44%) had stable disease. The first results of the therapeutic efficacy in patients with
SSTR-positive tumours with the somatostatin analogue [90Y-DOTA0,Tyr3]octreotate
(90Y-DOTATATE) were recently reported by Baum et al.43,44 Twenty-eight out of 75
(37%) patients had partial remission, and 39 out of 75 (52%) demonstrated stable
disease after therapy. Therefore, 90Y-DOTATATE might also be a promising 90Y-labelled
somatostatin analogue. Despite the differences in somatostatin analogues and
protocols used in the various 90Y-based PRRT studies, the reported results of therapy
in terms of complete and partial remission percentages, ranging up to 37% (Table 4),
indicated an improvement in therapeutic effectiveness compared with the studies with
111In-labelled octreotide.Figure 2. Baseline and follow-up data of a patient with carcinoid with liver metastases. (A) Post-therapy
scintigraphy after each cycle is shown (top row). Note the decrease of uptake of [177Lu-DOTA0,
Tyr3]octreotate on the last scintigraphy scan in comparison with the first (black arrows indicating the index
lesion). At 3 and 6 months after four cycles of therapy, the patient had a partial remission (O50% decrease in
tumour volume on computed tomography; white arrows indicate the index lesion) (bottom row). (B)
Regression of the tumour mass was accompanied by a decrease in serum concentration of alkaline
phosphatase (reference range 0–119 U/l), gamma-glutamyl transpeptidase (gamma-GT; reference range
0–49 U/l) and the tumour marker chromogranin A (reference range 10–100 ng/ml).
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The first results of [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) therapy were
described in a study of 35 patients with neuroendocrine GEP tumours, who had a
follow-up of 3–6 months after receiving their final dose.17 Patients were treated with
escalating dosages from 100 to 150, and a maximum of 200, mCi (3.7, 5.6 and
7.4 GBq, respectively) 177Lu-DOTATATE, up to a final cumulative dose of 600–800 mCi
(22.2–29.6 GBq), with treatment intervals of 6–9 weeks. The effects of the therapy on
tumour size were evaluable in 34 patients. Three months after the final administration,
a complete remission was found in one patient (3%), a partial remission in 12 (35%),
stable disease in 14 (41%) and progressive disease in seven (21%), including three
patients who died during the treatment period.
In an update on this treatment in 76 patients with GEP tumours,45 complete
remission was found in one patient (1%), partial remission in 22 (29%), minor
remission in 9 (12%), stable disease in 30 (40%), and progressive disease in 14
patients (18%). The effect of 177Lu-DOTATATE therapy on tumour size, uptake on
post-therapy scintigraphy, liver enzymes and the tumour marker chromogranin A in a
patient who showed partial remission is shown in Figure 2. Six out of 32 patients
who had induced stable disease or tumour regression after the therapy and were
also evaluated after 12 months (mean 18 months from therapy start) developed
progressive disease; in the other 26, the tumour response was unchanged. Median
time to progression was not reached at 25 months from the beginning of therapy. In
a more recent evaluation of response in a total of 131 GEP tumour patients, these
outcomes were confirmed, with a median time to progression of more than 36
months.46
Peptide receptor radionuclide therapy 605Comparison of the different treatments
Treatment with 90Y- and 177Lu-labelled somatostatin analogues is very encouraging in
terms of tumour shrinkage. However, direct comparison to evaluate the optimal
treatment remains difficult. Differences in treatment protocol, such as administered
doses, dosing schemes and the tumour response criteria used, can be responsible for
the observed differences in treatment outcome. Therefore, randomised controlled
trials are necessary to define the optimal PRRT and treatment scheme.SIDE-EFFECTS AND RADIATION TOXICITY
Adverse reactions observed after PRRT can be divided into direct side-effects and the
more delayed effects of radiotoxicity. Direct effects commonly mentioned during and
after therapy are nausea, vomiting and abdominal pain.17,30,34 In general, these side-
effects occur in a minority of patients and are easily treated with anti-emetics or pain
medication. Mild hair loss was observed in patients treated with 177Lu-DOTATATE, but
hair growth had normalised at follow-up 3–6 months after the last administration.17
Beside these mild side-effects, more serious toxicity may occur, especially to the boneTable 5. Side-effects in patients with somatostatin receptor-positive (gastroenteropancreatic and non-
gastroenteropancreatic) tumours treated with different radiolabelled somatostatin analogues.
Author Radioligand
Number
of patients
Grade 3–4 haematological toxicitya
Other
toxicity
Platelets
(%)
Haemo-
globulin
(%)
White
blood
cells (%)
Valkema et al6 [111In-DTPA0]
octreotide
50 10 15 2 3 AML/
MDS
Anthony et al30 [111In-DTPA0]
octreotide
27 7 11 7 3 Liver,
1 Renal
Bodei et al39 [90Y-DOTA0,Tyr3]
octreotide
40 7 3 7
Otte et al48 [90Y-DOTA0,Tyr3]
octreotide
29 3 7 0 4 Renalc
Waldherr
et al16
[90Y-DOTA0,Tyr3]
octreotide
39 0 3 0 1 Renal
Valkema et al41 [90Y-DOTA0,Tyr3]
octreotide
60 12 8 13 1 MDS,
1 Liver,
1 Renal
Kwekkeboom
et al45
[177Lu-DOTA0,-
Tyr3]octreotate
201 3 1 2 1 MDS,
2 Liverb,
1 Renal
Percentages are based on patient numbers. AML, acute myeloid leukaemia; MDS, myelodysplastic
syndrome. cNo amino acid infusion in half of the patients.
a Most of the mentioned haematological toxicities were transient. See reference for more detailed
information.
b D.J. Kwekkeboom et al, personal communication, 2004.
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are shown in Table 5.Haematological toxicity
Haematological toxicities of grade 3–4 for haemoglobin, white blood cells and platelets
were reported up to a maximum of 15%.16,30,39,45,47,48 In general, the decrease in blood
cell count was transient, and transfusion was only occasionally needed.
More serious side-effecs were reported from a clinical trial in which 50 patients
were treated with 111In-octreotide.6 Leukaemia and myelodysplastic syndrome were
reported in three patients who had been treated with total cumulative doses of over
2.7 Ci (100 GBq), with an estimated cumulative bone marrow radiation dose of about
3 Gy. One patient, who developed acute myeloid leukaemia 17 months after the first
dose of 111In-octreotide, had had chemotherapy and treatment with interferon before
PRRT. The other two patients, who had had no previous cytotoxic therapy, developed
myelodysplastic syndrome after more than 3 years. None of the 44 patients who were
treated with a cumulative dose lower than 100 GBq developed myelodysplastic
syndrome or leukaemia. In a phase I trial with 90Y-DOTATOC in which the objective
was to define the maximal tolerated single and four-cycle doses, one patient had
myelodysplastic syndrome 2 years after the start of PRRT; this patient had also had
previous chemotherapy.41 In the report by Kwekkeboom et al,45 who studied the
patients treated with 177Lu-DOTATATE as PRRT, one patient in the whole group of
patients who had been treated or were being treated up to that time (201 patients, 637
administrations) developed myelodysplastic syndrome. This patient had also previously
received chemotherapy.
In summary, haematological toxicity in PRRT is in general mild and reversible, and the
risk of developing myelodysplastic syndrome or leukaemia is low if certain dosing limits
are respected.Renal toxicity
Chelated somatostatin analogues are cleared predominantly by the kidneys. An
accumulation and retention of these analogues within the kidney occurs but is not SSTR
mediated.49 Because of the rapid clearance, [111In-DTPA0]octreotide can be safely
applied for diagnostic use without any damage to the kidneys.1,50 For therapeutic use,
however, the renal accumulation and the relatively long renal effective half-life of the
radiopharmaceutical can be dose-limiting. In external beam radiation therapy, renal
absorbed doses of 23 Gy (fractions of 2 Gy) may cause nephropathy in 5% of patients in
5 years, whereas 28 Gy leads to a 50% risk over the same period.51 However, since
PRRT is applied as continuous low-dose radiation with intracellular accumulation, a
maximum cumulative dose limit of 23 Gy may not be applicable.
The first reports on acute (6–12 months after radiation exposure) and late (1–5
years after exposure) renal side-effects appeared after the use of 90Y-DOTATOC
in various clinical trials.33,52–54 The results suggested that a cumulative dose of
90Y-DOTATOC of more than 7.4 GBq/m2 might be a risk factor for renal insufficiency.33
However, some years later, a case report of a patient who developed late-onset renal
insufficiency with a total cumulative dose of less than 7.4 GBq/m2 indicated that even
less radiation can cause renal damage at a later time point.53 In contrast, no renal
toxicity was found in patients treated with [111In-DTPA0]octreotide.6
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nephropathy may be explained by the difference in the particle range emitted (10 mm
versus approximately 12 mm, respectively). The Auger electrons emitted by 111In
within the tubular cells do not reach the radiosensitive glomeruli. This particle range
advantage might also be the reason why only one patient of a group of 201 patients
treated with 177Lu-DOTATATE developed renal failure.45 Although the number of
patients reported with radiation nephropathy was relatively low, and the potential
benefit for the patients outweighed the risk of occurrence of this severe complication,
it became clear that PRRT-induced radiation nephropathy was difficult to predict with
the currently applied maximum cumulative dose limits.
Two recent studies in which patients were treated with 90Y-DOTATOC provided
more insight into individual kidney dosimetry and its importance in PRRT.55,56 These
studies indicated that, apart from the total renal radiation dose, the dose volume,
fractionation rate and clinical parameters of hypertension, diabetes and age are relevant
risk factors for the development of a loss of renal function.
Kidney protection methods to prevent damage to the kidney from high absorbed
doses with each administration are obviously of importance. The most important
method currently used to reduce the renal uptake of radioactivity in PRRT is the use of
amino acid solutions, which can be easily co-administered during therapy. Preclinical
studies have shown that the infusion of positively charged amino acids, mainly L-lysine
and L-arginine, are able to reduce the tubular reabsorption of radiolabelled
somatostatin analogues in rats.57 Clinical studies have proved that co-infusion with a
combination of the L-lysine and L-arginine or a mixed amino acid solution on the day of
therapy led to a reduction in renal uptake of between 20 and 47%.29,39,58,59 Higher
doses of amino acids are more effective but have the disadvantage of inducing a higher
incidence of side-effects, such as nausea, vomiting and, especially with higher doses of
L-lysine, hyperkalaemia.59,60Liver toxicity
Most patients treated with PRRT in the clinical trials studied had liver metastases. The
extent of liver involvement ranged from a single lesion to diffuse liver involvement with
pronounced hepatomegaly. It is therefore not unlikely that PRRT can induce
hepatocellular radiation injury. In clinical practice, however, it may be difficult to
distinguish an increase of liver function parameters induced by radiation from a subtle
progression of liver metastases.
Anthony et al30 reported three patients (from a total of 27), treated with
111In-octreotide, in whom a temporary increase in liver function parameters (grade 3
liver toxicity on World Health Organization toxicity grading) was observed. All three
patients had a tumour replacement of more than 75% of their hepatic parenchyma and
treatment-associated necrosis on the computed tomography scans. In patients with less
extensive liver disease, changes in liver function parameters did not occur.
A significant increase in liver function parameters after the administration of
90Y-DOTATOC was reported in two studies.41,61 Valkema et al41 reported one
transient grade 3 toxicity in a group of 60 patients treated with 90Y-DOTATOC (phase I
study). In another study, 15 patients with proven liver metastases (of whom 12 had
extensive liver involvement, defined as 25% or more) from neuroendocrine tumours
were treated with three cycles of 120 mCi (4.4 GBq) each.61 In only four of these
15 patients, one or more of the three liver enzymes that were measured-serum
608 J. J. M. Teunissen et alaspartate aminotransferase, alanine aminotransferase and alkaline phosphatase-
increased-increased at least one grade, according to the World Health Organization
common toxicity criteria, from baseline to final follow-up measurement (4–6 weeks
post cycle 3). It was concluded that patients with diffuse SSTR-positive hepatic
metastases could be treated with a cumulative administered activity of 360 mCi
(13.2 GBq) of 90Y-DOTATOC with only a small chance of developing mild acute or
subacute hepatic injury.
In the group of patients treated with 177Lu-DOTATATE, significantly increased liver
function parameters (grade 4 liver toxicity) was evident in two patients after the first
cycle of treatment (D.J. Kwekkeboom, personal communication, 2004). One patient,
who suffered from a rapidly growing neuroendocrine tumour with extensive liver
involvement, clinically progressed to liver failure within 3 weeks and died shortly
thereafter. Whether the aggressive nature of the tumour or the PRRT-induced toxicity
led to this fatal condition remains unclear. The other patient, who after the first therapy
developed dyspnoea, acute abdominal pain and increased liver function parameters,
was hospitalised for several weeks. Gradually, the liver function parameters and
hyperbilirubinaemia returned to pre-therapy levels. Treatment with 177Lu-DOTATATE
was continued for 6 months after the first therapy with a reduced dose of 1.9 GBq
followed by a third administration of 4.1 GBq without any acute side-effects.CLINICAL PRACTICE
In patients with metastasised GEP tumours, for whom surgery is no longer an option,
PRRT can be an effective alternative therapeutic modality with limited side-effects. The
results in terms of tumour volume reduction, as shown in the different clinical trials, are
very encouraging and seem to compare favourably with chemotherapy. No randomised
controlled study has, however, been performed to confirm this.
Although proven effective in a substantial percentage of patients, PRRT has not been
widely recognised as alternative systemic therapy. Instead, the ‘wait-and-see’ approach
often remains the mainstay of initial management in patients with unresectable disease.
The rationale for this approach is found in the natural history of well-differentiated GEP
tumours not receiving treatment, in which tumours can be indolent for many years and
the well-being of patients, even with metastasised tumours, can be unchanged for many
years. However, the reported studies on PRRT clearly indicate that patients with
documented progressive disease or a substantial increase in symptoms can benefit from
this therapy. The recognition of the possible benefit of PRRT for patients with GEP
tumours is increasing, but its implementation within the whole therapeutic array is
rather poor. Factors that contribute to this include the fact that PRRT is a relatively new
therapeutic modality, the lack of approved radiopharmaceuticals, which is in part
related to increased governmental demands, and therapy-related costs.
Indications for peptide receptor radionuclide therapy
Candidates for PRRT are those patients with inoperable GEP tumours who have
progressive disease or symptomatology that is difficult to manage with medication. If it
is agreed that the malignancy is inoperable, the tumour has to be SSTR-positive,
based on tumour uptake on 111In-octreotide scintigraphy. Furthermore, the amount
of tumour uptake has to be equal to or higher than that of normal liver tissue
Table 6. Criteria for peptide receptor radionuclide therapy in patients with gastroenteropancreatic
tumours.
Inclusion
Sufficient tumour uptake on 111In-octreotide scintigrams
Haematology
Haemoglobin S5.0 mmol/l
White blood cell count S2–3.5!109/l
Platelet count S75–100!109/l
Kidney function
Creatinin (serum) %150 mmol/l or creatinine clearance S40 ml/min
Karnofsky Performance Status S50
Life expectancy O6 months
Exclusion
Chemotherapy within 6 weeks prior to the start of treatment
Pregnancy/lactation
Peptide receptor radionuclide therapy 609(according to criteria previously described by Krenning et al).10 High uptake during
111In-octreotide scintigraphy has been shown to be correlated with tumour regression
after PRRT.17 Additionally, because of the radiation to the bone marrow and the risk of
temporary bone marrow suppression, patients need to fulfil certain minimal
haematological criteria. Kidney function has to be determined before therapy
to exclude patients with signs of impending renal failure (glomerular filtration rate
!40 ml/minute). The presence of bone metastases, which occur in a minority of
patients, is no exclusion criterion. As a rule, if a tumour response occurs, all tumour
sites decrease in size. However, cystic and bone lesions seem to respond in a more
protracted way than the more common, solid liver metastases. Up until now, no
systematic study has been performed to address the issue of a possible differential
response of metastases based on their location. The full patient selection criteria are
summarised in Table 6.Timing of therapy
There is currently no consensus about when to start PRRT in patients with GEP
tumours. The stage of disease at which the diagnosis is made is highly variable and
ranges from a localised, non-metastatic primary tumour to more advanced or end-stage
disease with hepatomegaly and ascites. In a recent report in which the relationship
between delay of diagnosis, extent of disease and survival in 115 patients with
carcinoid was studied, a mean delay in the diagnosis of 66 months was found.62 It was
concluded that the diagnosis of carcinoid is difficult, and therefore a delay of diagnosis
by physicians is common. Strikingly, the delay of the diagnosis did not correlate with the
extent of the disease. However, the extent of the disease did correlate with survival.
Patients with primary tumours and lymph node metastases were less likely to die of
carcinoid disease than patients with hepatic metastases, carcinomatosis or extra-
abdominal metastases.
Unfortunately, reports on PRRTwith explicit survival data are few. In the multicentre
trial with 111In-octreotide,6 it was reported that PRRT for end-stage patients with a
higher tumour burden was less likely to have a favourable outcome than for patients with
lower tumour burden or in a better general condition. Survival data in a group of
610 J. J. M. Teunissen et al27 patients treated with 111In-octreotide presented by Anthony et al30 suggested a
survival benefit in patients treated with 111In-octreotide. The number of patients studied
was, however, low, and the survival data of the treated group were compared with data
from a historical control group. In the studies with 177Lu-DOTATATE, it was suggested
that, because of the high success rate of the therapy, the low incidence of side-effecs and
the high median time to progression (O36 months), its use can be advocated in patients
with metastasised, unresectable GEP tumours without waiting for tumour pro-
gression.17,63
Another argument in favour of early treatment is that neuroendocrine tumours can
dedifferentiate in the course of the disease and thereby lose the expression of SSTRs.
Treatment with radiolabelled somatostatin analogues will then be impossible.17
However, whether early treatment would benefit patients with metastasised,
unresectable GEP tumours in terms of longer survival remains to be studied and should
imply randomisation into groups with and without PRRT. At this moment, when there
seems to be proof that PRRT is an effective therapy, such a survival study seems unethical.
Another issue, regarding the question whether we should treat patients with PRRT
or not at an early stage of the disease, is the benefit in terms of clinical response and
quality of life. Not all studies address this issue. There is, however, a growing awareness
of its importance in clinical oncology trials, especially in therapies for which cure is notAll REGR SD PD
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Figure 3. Global health/quality of life scale scores of all the patients (nZ50) and the different outcome groups
according to tumour evaluation before (hatched bars) and 3 months after (grey bars) 177Lu-octreotate
therapy. REGR, regression (complete, partial and minor remission); SD, stable disease; PD, progressive
disease. Standard errors of the mean are shown; *P!0.05; **P!0.01; NS, not significant (two-sided analysis
of variance; P!0.05 was considered significant). (Modified from Teunissen et al.66).
Peptide receptor radionuclide therapy 611the primary goal and survival gains are low or unknown.64 As a consequence, the more
recent PRRT reports have included data on the clinical effectiveness of therapy. Two
studies with 90Y-DOTATOC provided evidence for a favourable clinical response in 60–
70% of the patients.47,65 In patients treated with 177Lu-DOTATATE, quality of life
assessment showed a significant improvement in the global health/quality of life score
(D scoreC9.2, scale range 0–100, P!0.01), especially in those patients with proven
tumour regression (D scoreC10.5, P!0.05) (Figure 3).66 Although the assessment
methods for identifying clinical changes differ in these studies, the combined results
suggest that patients may experience a clinical benefit from PRRT.FUTURE DEVELOPMENTS
A direction of future research to improve current PRRT for GEP tumours includes the
development of new stable somatostatin analogues with a high affinity for the different
SSTR subtypes. The new analogue [DOTA0-1-naphthyl3]octreotide (DOTANOC), for
example, is an analogue that has a high affinity for SSTR2, SSTR3 and SSTR5.67 It might
therefore be a promising analogue to be used for treatment of patients with tumours
that not bear only SSTR2, but also express SSTR3 and/or SSTR5. Furthermore,
combined treatment with different radiolabelled somatostatin analogues, analogous to
the favourable response with combinational chemotherapy in solid tumours compared
with single-agent therapy, is of great interest. This approach will of course be limited by
the combined toxicity of the radiolabelled peptides. Preclinical PRRT studies with 90Y-
DOTATOC and 177Lu-DOTATATE indicate that there is an optimal tumour size in
terms of the efficacy of tumour reduction for each radionuclide. As most patients have
metastatic disease with tumours of different sizes, combination PRRT could achieve
higher cure rates compared with single-agent therapy.
Higher cure rates are possible when the density of expressed SSTRs is
enhanced. In vitro and in vivo studies show that the irradiation of neuroendocrine
AR42J (rat pancreatic tumour) cells can upregulate the expression of SSTR2 and
gastrin receptors.68 PRRT after the upregulated expression of SSTR2 may lead to a
higher uptake of the radiolabelled peptide and consequently a higher therapeutic
efficacy.
Most research in PRRT is focused on the different SSTR subtypes. Neuroendocrine
tumours may, however, coexpress other tumour-specific peptides, such as vasoactive
intestinal peptide, cholecystokin, bombesin and GLP-1 receptors.69 The concomitant
expression of these receptors could be used in the future in a multireceptor PRRT to
target more efficiently GEP tumours in each patient individually. This approach could,
especially in tumours with a heterogeneous or even a reciprocal receptor distribution,
be very favourable in terms of achieving a more homogenous distribution of the
absorbed radiation dose within the tumour mass.
The combination of PRRT with surgery and/or chemotherapy as a multimodality
treatment strategy is of interest and requires the start of randomised trials to prove
whether current results can be improved. Studies that can also be considered are
the use of PRRT combined with surgery in an adjuvant setting to irradiate occult
metastases, or PRRT as debulking therapy followed by surgery in patients with
inoperable but limited local disease. External beam radiotherapy in combination with
chemotherapy such as gemcitabine, which is a known potent radiation sensitiser, has
been shown to have favourable effects in patients with non-small-cell lung cancer.70
612 J. J. M. Teunissen et alAlthough the patients were treated with external radiotherapy, gemcitabine
and other radiosensitising agents with concurrent PRRT might prove effective in
the future.SUMMARY
PRRT holds great promise for the future regarding the treatment of various cancers.
Using radiolabelled peptides, which bind with high affinity to specific receptors on
cancer cells, it is possible to target the cancer efficiently. In GEP tumours, radiolabelled
somatostatin analogue therapy has been proven to be effective. Dose-limiting organs
are the bone marrow and the kidneys. With the currently used maximum allowed dose,
PRRT is relatively safe, and serious side-effects are rare. It is impossible to conclude
from the available literature which radiolabelled somatostatin analogue can be regarded
as the most effective therapy. Also, the development of therapy strategies with
combinations of different radionuclides, which is underway, is of interest as these
strategies may in future provide an increase in therapeutic efficacy.Practice points
† PRRTwith b-emitting agents such as 90Yand 177Lu can induce tumour shrinkage
in patients with SSTR-positive GEP tumours
† octreotide scintigraphy is used to select candidates for PRRT
† a high uptake during octreotide scintigraphy is correlated with a favourable
outcome of PRRT
† the co-administration of amino acids during PRRT is essential to minimise the
risk of renal toxicity
† blood examination before each cycle of PRRT is necessary as bone marrow
suppression is a known risk of PRRT
Research agenda
The following areas are of interest in optimising PRRT:
† the development of new somatostatin analogues with a high affinity for different
SSTR subtypes
† randomised controlled (multicentre) trials to compare the therapeutic efficacy
of 90Y- and 177Lu-labelled somatostatin analogues, and their use in combination
† the development of different peptide analogues with a high affinity
† the implementation of multimodality treatment strategies:
– surgery with adjuvant PRRT
– PRRT for debulking before surgery
– chemotherapy as a radiosensitiser for PRRT
† methods to upregulate the expression of SSTRs in vivo
† the reduction of kidney and bone marrow uptake
**
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